Combinations, Proper Sequencing Needed for Optimal HR+ Breast Cancer Treatment
October 6th 2016William J. Gradishar, MD, discusses the need for new strategies that could alter the landscape of HR-positive breast cancer for the better, and how these methods can overcome drug resistance and delay disease progression.
Read More
Large Analysis Sheds Light on Risk Factors for Non-Cirrhotic NASH-Associated HCC
September 11th 2016About one quarter of patients with nonalcoholic steatohepatitis-associated hepatocellular carcinoma present without cirrhosis at diagnosis, suggesting a crucial subset of patients for future research with implications for HCC screening and surveillance.
Read More
TILs Advancing as Melanoma Immunotherapy Option
March 31st 2016After nearly 30 years of research, tumor-infiltrating lymphocyte technology is being investigated as a means of producing personalized immunotherapy for patients with metastatic melanoma in a small clinical trial that may help open the door for broader application in other solid tumor types.
Read More
Expert Discusses Emerging Agents in ER+ Metastatic Breast Cancer
March 23rd 2016Joyce O’Shaughnessy, MD, discusses how four agents—palbociclib (Ibrance), pembrolizumab (Keytruda), abemaciclib (LY2835219), and buparlisib (BKM120)—are worth examining in estrogen receptor-positive breast cancer.
Read More
World Cancer Day Aims to Unite Millions to Increase Awareness, Reduce Global Burden
February 4th 2016With more than 8 million cancer deaths worldwide every year, the Union for International Cancer Control hopes to encourage both groups and individuals to reflect on how they can help reduce the global burden of cancer on February 4, World Cancer Day.
Read More
New Model Supports Use of Palliative Care With Radiotherapy for Bone Metastases
December 4th 2015A novel service model that incorporated palliative care measures and shorter radiation treatment was associated with fewer unfinished treatments with radiation, shorter hospital stays, and increased use of palliative care for patients with bone metastases.
Read More
Experts Offer Insight on BRCA1/2 Testing and Prophylactic Procedures
May 4th 2015Optimal testing strategies for breast and ovarian cancer associated with mutations in the BRCA1/2 genes, including when to start testing and which prophylactic approach to pursue, have remained a topic of debate.
Read More
Oncology Nurses Poised to Make a Difference in Managing “Silent” Portal Vein Thrombosis
April 28th 2015Portal vein thrombosis is a dangerous and often overlooked side effect of certain gastrointestinal malignancies such as liver and pancreatic cancer, that oncology nurses need to be more proactive in managing.
Read More
Lapatinib Falls Short Versus Trastuzumab, Adding Clarity to Frontline HER2-Positive MBC Strategy
March 20th 2015First-line treatment with lapatinib and a taxane failed to improve progression-free survival versus trastuzumab plus a taxane in patients with HER2-positive metastatic breast cancer in the MA.31 trial.
Read More
Expert Discusses Frontline Bortezomib in MCL
March 18th 2015To gain new insight on the phase III LYM-3002 study and bortezomib's use in the frontline MCL setting, OncLive interviewed Andrew Evens, DO, MSc, director of the Tufts Cancer Center and chief of the Division of Hematology/Oncology at Tufts University School of Medicine.
Read More